Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October ...

In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

The deals keep rolling in, with Lilly penning a $7 billion pact for gene delivery biotech Kelonia Therapeutics and UCB taking ...

While prominent physicians can provide companies with valuable guidance during development, their perspective is limited when ...

Finding the right people for critical open roles can be difficult even for biopharma leaders. In this column, Kaye/Bassman’s ...

As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is ...

The newly approved HIV drug Idvynso will also help Merck diversify as loss of exclusivity looms over its top-selling product, ...

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...